The major goals of the Pediatric Cancer Program are: 1) to increase understanding of the biology of pediatric malignancies through comprehensive molecular, proteomic and genomic analysis of these diseases, 2) to use information from these studies to improve diagnostic, prognostic and therapeutic approaches for pediatric cancers, 3) to identify novel molecular targets that may be exploited therapeutically, 4) to study the genetic pre-disposition for selected pediatric cancers, 5) to identify effective therapies and conduct innovative Phase I and Phase II trials, and 6) to study the late effects of childhood cancer therapy and improve outcomes of survivors. The Program also mentors and trains pediatric oncology fellows and NCI-funded post-fellowship clinical research trainees. The Pediatric Program is located at Texas Children's Hospital and is one of the largest pediatric cancer programs in the nation. Approximately 550 new pediatric cancer patients are seen each year. The Pediatric Program Leader is David Poplack, M.D.;the Co-Leader is Ching Lau, M.D, Ph.D. The Pediatric Program has 23 Research Members, 22 Members and 25 Clinical Investigators from a variety of Departments at Baylor College of Medicine (including Pediatrics, Surgery, Neurosurgery, Radiation Therapy, Ophthalmology, and Pathology) and from the Bio-Engineering Department at Rice University. Last year, the Program had $3,734,599 in support from the NCI and $7,673,535 in peer-reviewed funding. Members of the program published 230 cancer related publications in peer-reviewed journals of which 53% represented intraprogrammatic collaborations and 27% interprogrammatic collaborations. Major research themes of the Pediatric Program include: 1) biologic and therapeutic studies of pediatric solid tumors, 2) pediatric cancer developmental therapeutics, and 3) pediatric brain tumor research. The Pediatric Program is one of the most active pediatric cancer research programs in the U.S. The Program has 221 IRB approved, cancer related protocols. Of these 128 are clinical trials, 25 of which were developed by Pediatric Program investigators. The Program conducts numerous clinical trials through its formal affiliations with the NCI-supported Children's Oncology Group, Pediatric Brain Tumor Consortium and New Advances in Neuroblastoma Treatment Network. Clinical research is performed in the outpatient and inpatient facilities of Texas Children's Hospital. Numerous inter-and intra-programmatic and inter-institutional collaborations are carried out to enhance both laboratory and clinical research programs. Regular interactive and didactic conferences and meetings are an integral part of the exchange of scientific knowledge within and outside the Program. The Pediatric Program conducts significant outreach activities on a local, regional, national and international level.

Public Health Relevance

The Pediatric Cancer Program performs clinical and laboratory research aimed at improving our understanding the biology of childhood cancer. The main goal of this research is to develop new treatments that improve the outlook for patients with these diseases. The results of the research conducted in this program is made available to cancer researchers worldwide.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-06
Application #
8376817
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
6
Fiscal Year
2012
Total Cost
$14,173
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
De Maio, Antonia; Yalamanchili, Hari Krishna; Adamski, Carolyn J et al. (2018) RBM17 Interacts with U2SURP and CHERP to Regulate Expression and Splicing of RNA-Processing Proteins. Cell Rep 25:726-736.e7
Singh, Sunita; Jangid, Rahul K; Crowder, Alyssa et al. (2018) Foxi3 transcription factor activity is mediated by a C-terminal transactivation domain and regulated by the Protein Phosphatase 2A (PP2A) complex. Sci Rep 8:17249
Lulla, Premal D; Hill, LaQuisa C; Ramos, Carlos A et al. (2018) The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol 16:375-386
Reineke, Lucas C; Cheema, Shebna A; Dubrulle, Julien et al. (2018) Chronic starvation induces noncanonical pro-death stress granules. J Cell Sci 131:
Bayrer, James R; Wang, Hongtao; Nattiv, Roy et al. (2018) LRH-1 mitigates intestinal inflammatory disease by maintaining epithelial homeostasis and cell survival. Nat Commun 9:4055
Charendoff, ChloƩ I; Bouchier-Hayes, Lisa (2018) Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation. J Vis Exp :
Cardona, Sandra M; Kim, Sangwon V; Church, Kaira A et al. (2018) Role of the Fractalkine Receptor in CNS Autoimmune Inflammation: New Approach Utilizing a Mouse Model Expressing the Human CX3CR1I249/M280 Variant. Front Cell Neurosci 12:365
Zhang, Manqi; Suarez, Egla; Vasquez, Judy L et al. (2018) Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene :
Chiang, Yun-Chen; Park, In-Young; Terzo, Esteban A et al. (2018) SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Res 78:3135-3146
Choi, Byung-Kwon; Dayaram, Tajhal; Parikh, Neha et al. (2018) Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proc Natl Acad Sci U S A 115:10666-10671

Showing the most recent 10 out of 991 publications